India yanks license of uncooperative Chinese supplier

Bulk drugmaker Chongiqing Daxin has lost its license to export drugs to India by refusing to let Indian officials inspect its facility. On its maiden inspection trip to the People's Republic, a three-member team from the Central Drugs Standard Control Organization (CDSCO) was shut out just the one time and completed five other inspections. That brings to ten the number of canceled registration certificates and related import licenses of Chinese companies.

The decision to audit Chinese drug manufacturing units was made after inspections of the India-based facilities of those drugmakers. Poor product quality and failure to comply with good manufacturing practices were cited. 

Based on those findings, the Drug Controller General of India shortlisted 11 Chinese manufacturing units for inspection. It had just received an OK from the Health Ministry to make inspections beyond national borders. 

India is the largest importer of Chinese bulk drugs, reports Times of India. Nearly half of the 272 bulk drug manufacturers registered in India are Chinese companies. Italy is the second largest, at 55 registered companies.

Italy: prepare for visitors.

- here's the story

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.